BioSpace News Archive

CellFE Inc., a life sciences tools company commercializing a microfluidics-based cellular engineering platform, today announced its CEO Alla Zamarayeva, PhD, will be presenting at two conferences in January.

TheracosBio today announced that BRENZAVVY® (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, will be available to Independent Pharmacy Cooperative (IPC) members.

Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”) today announced that the first patient has been randomized in China in the global NATiV3 Phase III clinical trial and provided an update on its clinical development program.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) announced today its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45AM Pacific Time.

ResMed is conducting a voluntary global field action to update its guides for all masks with magnets to inform users about potential magnetic interference when magnets are near certain implants and medical devices in the body.

10x Genomics, Inc., a leader in single cell and spatial biology, announced the launch of its Xenium Catalyst Network, a global group of technically qualified research institutions that will accelerate access to Xenium proof-of-concept data for researchers worldwide.

BioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, announced several initiatives to enhance corporate governance and long-term shareholder value creation.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced the closing of the expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM).

Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, has appointed Sanjeev Luther as President and Chief Executive Officer and a member of the company’s Board of Directors, effective January 1, 2024.

Renexxion Ireland Limited (“Renexxion”) announced today that it has completed a successful pre-Investigational New Drug (pre-IND) consultation with the U.S. Food and Drug Administration (U.S. FDA) to discuss development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease (PPI-nrsGERD).